NBIA HUNGARY SIGNS AN AGREEMENT OF COLLABORATION WITH THE PABLO DE OLAVIDE UNIVERSITY OF SEVILLE (SPAIN) TO START THE BRAINCURE FOR MPAN RESEARCH PROJECT.
During this last week, the collaboration agreement between the NBIA HUNGARY Association and the Pablo de Olavide University of Seville has been formalized, with which a new research line is opened for one of the ENACH subtypes called MPAN (neurodegeneration associated with the mitochondrial membrane protein).
This new line of research follows the methodology of BRAINCURE which consists of trying to identify drugs already available in the market that, either alone or combined with each other, can be a therapeutic option for PATIENTS OF THIS GENERATION.
BRAINCURE for MPAN, in a preliminary way, has already identified 3 drugs approved by the EMA and the FDA that have been positive in the induced neurons of MPAN patients and, with the formal opening of this new line of research, it is foreseen that the number of already commercial drugs is increased and with it, the chances of success.
BRAINCURE has a marked profile of translational science (from laboratory to patient), therefore, it works with the skin cells of each of the patients that are cultured to fibroblasts and, these, to neurons induced by direct reprogramming.
BRAINCURE is directed by Professor Sánchez Alcázar and already covers the following ENACH subtypes: PKAN, PLAN, BPAN and now MPAN.
Ovidiu BOTEZAN, President NBIA HUNGARY, learned first-hand about the BRAINCURE philosophy, as well as the promising preliminary situation at MPAN. This, together with the clinical results obtained in PKAN patients with this methodology, have encouraged NBIA HUNGARY to finance the start-up of BRAINCURE for MPAN.
In addition to financial support, NBIA HUNGARY also fully participates in the visibility and support of BRAINCURE in Hungary and internationally, since financial support from more patients or patient associations will be necessary so that the project can continue over time.
With this agreement, there are now 3 patient associations that, at the international level, have decided to support the BRAINCURE philosophy of trying to use existing science and drugs to seek therapies for PATIENTS OF THIS GENERATION, it is AIDNAI (NBIA FRANCE ) NBIA HUNGARY and ENACH Association (Spain).
The contact details to contact NBIA HUNGARY are:
Ovidiu BOTEZAN (President)
Email: ovidiubotezan@gmail.com
Website: http://www.nbia.hu